- Motley Fool•4 hours ago
The company and the FDA concluded a successful end-of-phase 2 meeting for its lead drug candidate.
- Investopedia•7 hours ago
Ziopharm’s brain cancer drug, Ad-RTS-hIL-12, secured approval from the FDA to proceed in a clinical trial.
- GlobeNewswire•13 hours ago
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma
BOSTON, March 27, 2017-- ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. ...
ZIOP: Summary for ZIOPHARM Oncology Inc - Yahoo Finance
ZIOPHARM Oncology, Inc. (ZIOP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||6.70 x 2000|
|Ask||7.10 x 100|
|Day's range||5.79 - 6.89|
|52-week range||4.45 - 9.19|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-5.06|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|